Erlmeier F - Search Results

1

Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines.

Kneissl J, Hartmann A, Pfarr N, Erlmeier F, Lorber T, Keller S, Zwingenberger G, Weichert W, Luber B. Kneissl J, et al. Among authors: erlmeier f. J Cancer Res Clin Oncol. 2017 Apr;143(4):573-600. doi: 10.1007/s00432-016-2308-z. Epub 2016 Dec 8. J Cancer Res Clin Oncol. 2017. PMID: 27933395 Free PMC article.

2

PD-1/PD-L1 expression in chromophobe renal cell carcinoma: An immunological exception?

Erlmeier F, Hartmann A, Autenrieth M, Wiedemann M, Ivanyi P, Steffens S, Weichert W. Erlmeier F, et al. Med Oncol. 2016 Nov;33(11):120. doi: 10.1007/s12032-016-0833-x. Epub 2016 Sep 30. Med Oncol. 2016. PMID: 27696122

3

[c-MET Oncogene in Renal Cell Carcinomas].

Erlmeier F, Weichert W, Autenrieth M, Ivanyi P, Hartmann A, Steffens S. Erlmeier F, et al. Aktuelle Urol. 2016 Dec;47(6):475-479. doi: 10.1055/s-0042-115401. Epub 2016 Dec 22. Aktuelle Urol. 2016. PMID: 28006830 Review. German.

4

The Role of PD-L1 Expression and Intratumoral Lymphocytes in Response to Perioperative Chemotherapy for Urothelial Carcinoma.

Erlmeier F, Seitz AK, Hatzichristodoulou G, Stecher L, Retz M, Gschwend JE, Weichert W, Kübler HR, Horn T. Erlmeier F, et al. Bladder Cancer. 2016 Oct 27;2(4):425-432. doi: 10.3233/BLC-160067. Bladder Cancer. 2016. PMID: 28035323 Free PMC article.

5

c-Met in chromophobe renal cell carcinoma.

Erlmeier F, Ivanyi P, Hartmann A, Autenrieth M, Wiedemann M, Weichert W, Steffens S. Erlmeier F, et al. Med Oncol. 2017 Feb;34(2):15. doi: 10.1007/s12032-016-0874-1. Epub 2016 Dec 29. Med Oncol. 2017. PMID: 28035577

6

PD-L2: A prognostic marker in chromophobe renal cell carcinoma?

Erlmeier F, Weichert W, Autenrieth M, Wiedemann M, Schrader AJ, Hartmann A, Ivanyi P, Steffens S. Erlmeier F, et al. Med Oncol. 2017 May;34(5):71. doi: 10.1007/s12032-017-0926-1. Epub 2017 Mar 28. Med Oncol. 2017. PMID: 28353093

7

Prognostic impact of PD-1 and its ligands in renal cell carcinoma.

Erlmeier F, Weichert W, Schrader AJ, Autenrieth M, Hartmann A, Steffens S, Ivanyi P. Erlmeier F, et al. Med Oncol. 2017 Jun;34(6):99. doi: 10.1007/s12032-017-0961-y. Epub 2017 Apr 21. Med Oncol. 2017. PMID: 28432616 Review.

8

[Adult autopsies during the past decade in Germany : Data from two university hospitals].

Erlmeier F, Weichert W, Knüchel R, Andruszkow J. Erlmeier F, et al. Pathologe. 2017 Sep;38(5):430-437. doi: 10.1007/s00292-017-0319-4. Pathologe. 2017. PMID: 28698908 German.

9

[Fetal autopsies : Relic or still a gold standard?].

Andruszkow J, Weichert W, Braunschweig T, Knüchel-Clarke R, Erlmeier F. Andruszkow J, et al. Among authors: erlmeier f. Pathologe. 2017 Sep;38(5):438-447. doi: 10.1007/s00292-017-0324-7. Pathologe. 2017. PMID: 28741114 German.

10

Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab.

Eckstein M, Erben P, Kriegmair MC, Worst TS, Weiß CA, Wirtz RM, Wach S, Stoehr R, Sikic D, Geppert CI, Weyerer V, Bertz S, Breyer J, Otto W, Keck B, Burger M, Taubert H, Weichert W, Wullich B, Bolenz C, Hartmann A, Erlmeier F. Eckstein M, et al. Among authors: erlmeier f. Eur J Cancer. 2019 Jan;106:234-243. doi: 10.1016/j.ejca.2018.11.007. Epub 2018 Dec 5. Eur J Cancer. 2019. PMID: 30528808

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

45 results

Search Page